Skip to main content
An official website of the United States government

Fam-Trastuzumab Deruxtecan-nxki

Placeholder slot
 (fam-tras-TOO-zoo-mab DEH-rux-TEE-kan)

Fam-trastuzumab deruxtecan-nxki is a type of targeted therapy drug called an antibody–drug conjugate. Trastuzumab is a monoclonal antibody that is chemically linked to a drug called deruxtecan that blocks an enzyme called topoisomerase I. The monoclonal antibody binds to HER2, a protein found in large amounts on some cancer cells. The linked drug enters these cells, damaging their DNA and killing them. Fam-trastuzumab deruxtecan-nxki also induces a type of immune reaction that kills surrounding cells.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Fam-trastuzumab deruxtecan-nxki is approved to treat adults with:

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that fam-trastuzumab deruxtecan provides a clinical benefit in these patients.

Fam-trastuzumab deruxtecan-nxki is also being studied in the treatment of other types of cancer.

More About Fam-Trastuzumab Deruxtecan-nxki

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Fam-trastuzumab Deruxtecan-nxki - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Enhertu Marks First Targeted Therapy for HER2-Mutant Lung Cancer

Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer

Targeted Cancer Therapies

Enhertu May Be Preferred Therapy for Some Metastatic Breast Cancers

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Fam-trastuzumab Deruxtecan-nxki - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: